An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Incyte Corporation
Centre Paul Strauss
Massachusetts General Hospital
Adaptimmune
Abramson Cancer Center at Penn Medicine
Tesaro, Inc.
Hospices Civils de Lyon
University of California, San Diego
Hummingbird Bioscience
BeiGene
Incyte Corporation
Incyte Corporation
Hopitaux Prives de Metz, Groupe UNEOS
Incyte Corporation
Trishula Therapeutics, Inc.
University of Washington
Bank of Cyprus Oncology Centre
Biogen
University of California, Irvine
Scholar Rock, Inc.
AstraZeneca
University of Washington
Indiana University
NeoTX Therapeutics Ltd.
Cedars-Sinai Medical Center
University of Washington
Symphogen A/S
Daiichi Sankyo
Acepodia Biotech, Inc.
Astellas Pharma Inc
Vincerx Pharma, Inc.
Shanghai Chest Hospital
National Cancer Institute (NCI)
Cedars-Sinai Medical Center
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Pfizer
University of California, San Francisco
Novartis
NextCure, Inc.
Centre Leon Berard
AstraZeneca
Rutgers, The State University of New Jersey
Pfizer
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Providence Health & Services